MedTrace Logo

Study Evaluating AMG 424 in Subjects With Multiple Myeloma

NCT03445663 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2023-03-07

No results posted yet for this study

Summary

A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.

Conditions

  • Relapsed/ Refractory Multiple Myeloma

Interventions

DRUG

AMG 424

Subjects will receive IV infusions of AMG 424

Sponsors & Collaborators

  • Xencor, Inc.

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-31
Primary Completion
2020-06-19
Completion
2020-06-19
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03445663 on ClinicalTrials.gov